Investor Presentaiton

Trusted, long-term partner for global (bio-)pharma customers gsk novo nordisk Johnson & Johnson MERZ Lilly Number of clients 2020 21% Lonza Selected (bio-)pharma customers... Key statistics High level of recurring customers Number of clients & order intake share by type of client(1) 20% 10% 00 60% 30% Order intake 2020 59% Loyal customers Share of top 50 customers over 2012-2020 contributing to 75% of total order intake over last 9 years (1) 14% Top 50 clients 2012-2020 86% Baxter moderna™ Roche SANOFI NOVARTIS Recurring customers (2018-2020) New clients (2019 & 2020) Opportunistic clients Limited customer concentration Total order intake 2018-2020 per customer(2) Recurring clients (Continuous new order intake) New clients (First order intake) Large exposure to biopharma market Total order intake 2018-2020 per end market (2)(3) abbvie GILEAD 24% 15% 17% 43% 81% 4% 14% Pfizer Takeda November 2023 SKAN Group AG Investor Presentation (1) (2) 723 ■Top 1-5 ■Top 6-10 ■Top 11-20 Rest (Bio-)pharma ■CMO Cell & Gene Analysis based on customers of SKAN AG (SKAN AG includes almost all of SKAN's projects while Service & Consumables may be ordered on the local subsidiary level). Analysis based on customers of SKAN AG and Aseptic Technologies. (3) Analysis based on management estimates and suffers from limited customer disclosure on actual use of SKAN's equipment. (Bio-)pharma includes Pharma and Vaccines. Customers of Aseptic Technologies classified as Cell & Gene (or CMO if a clear distinction can be made). 12 SKAN

View entire presentation